

NeuroScientific Partners with Leading Biologic Manufacturer

NeuroScientific Biopharmaceuticals Ltd (ASX: **NSB**) (“**NeuroScientific**” or “**the Company**”) is pleased to announce that it has commenced the transfer of its patented manufacturing process for its mesenchymal stromal cells from Cell and Tissue Therapy WA (Royal Perth Hospital) to Q-Gen Cell Therapeutics (Q-Gen) of QIMR Berghofer Medical Research Institute (QIMR Berghofer).

The Company’s subsidiary, Isopogen Australia Opco Pty Ltd, had previously signed a manufacturing contract with QIMR Berghofer, under which Q-Gen would undertake manufacturing process development, scale-up and clinical grade manufacture of the Company’s proprietary StemSmart™ platform technology.

Q-Gen, located within QIMR Berghofer in Brisbane, is one of the largest cell therapy contract manufacturers in Australia, with 13 cleanrooms dedicated to cell manufacturing and quality control. Q-Gen specialises in manufacturing cellular immunotherapies for clinical trials, both national and international.

Q-Gen, which holds a TGA licence for cell therapy manufacture and has more than 25 years in cell therapy manufacturing for industry, has the experience, expertise and capacity to manufacture StemSmart™. The commencement of the technology transfer to Q-Gen is an important milestone for the Company to establish its cell manufacturing and enable it to undertake further clinical trials and pursue commercial opportunities.

CEO of NeuroScientific, Nathan Smith commented: “We are very pleased to be partnering with Q-Gen given their extensive experience in manufacturing, process development and GMP production of biologic products for clinical trials. This relationship will allow the Company to scale the manufacturing of its StemSmart™ technology to address substantial market opportunities.”

COO of QIMR Berghofer, Dr Stephen Weller, said: “QIMR Berghofer is delighted that NeuroScientific Biopharmaceuticals has selected the Q-Gen Cell Therapeutics facility to manufacture their GMP cell therapy. Q-Gen’s commitment to advancing cell therapies means we look forward to a long-term partnership with the Isopogen team and bringing their StemSmart™ technology to the clinic to improve the lives of chronically ill patients.”

The StemSmart™ technology is a proprietary method for the manufacture of human allogeneic mesenchymal stromal cells that have shown efficacy in serious clinical conditions such as Crohn’s disease and graft versus host disease.

For personal use only

This announcement is authorised by the Board of NeuroScientific Biopharmaceuticals Ltd.

-ENDS-

For more information please contact:

Paul Fry
Director
pfry@stemsmart.com.au
+61 (0) 422 001 188

Chris Achurch
Company Secretary
chris@westarcapital.com.au
+61 8 6268 2641

About NeuroScientific Biopharmaceuticals Ltd

NeuroScientific Biopharmaceuticals Limited (ASX: NSB) is a biotechnology company focused on the development of novel therapeutics targeting immune-mediated inflammatory disorders. The Company's research is centred on modulating pathological immune responses involved in chronic and degenerative conditions, particularly where current therapeutic options demonstrate limited efficacy or durability. NSB applies advanced preclinical and translational strategies to support the development of first-in-class or best-in-class biologics addressing significant unmet clinical need.

Targeting Crohn's Disease with StemSmart™ Technology

Following the acquisition of Isopogen WA Ltd, NSB is prioritizing the application of its proprietary StemSmart technology through a SAS program targeting fistulising Crohn's disease—a severe and treatment-resistant form of the condition. If early outcomes from this access program are favourable, the Company intends to progress to a Phase 1/2 clinical trial to further evaluate safety and preliminary efficacy. This initiative aligns with NSB's broader strategy to obtain regulatory and reimbursement approval for its MSC therapy both in Australia and internationally, with the goal of making the treatment available to patients with fistulising and refractory Crohn's disease, for whom current therapies remain inadequate.

About EmtinB™

EmtinB™ is a peptide-based compound that binds to surface-based cell receptors from the LDLR family, activating intracellular signalling pathways that stimulate neuroprotection, neuroregeneration and modulate neuroinflammation. EmtinB™ is modelled on a specific active domain of the complex human protein called Metallothionein-IIA, which is produced as part of the human body's innate immune response to cell injury. Our preclinical research has established that EmtinB™ is highly specific and selective for its target receptor, safe and well tolerated at high concentrations.